Last reviewed · How we verify
active oseltamivir
Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, preventing viral spread.
Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, preventing viral spread. Used for Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age, Prophylaxis of influenza A and B in patients ≥1 year of age.
At a glance
| Generic name | active oseltamivir |
|---|---|
| Also known as | Tamiflu |
| Sponsor | University of Oxford |
| Drug class | Neuraminidase inhibitor |
| Target | Influenza neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Oseltamivir is a prodrug that is metabolized to its active form, oseltamivir carboxylate, which selectively inhibits influenza neuraminidase enzymes. By blocking neuraminidase activity, the drug prevents cleavage of sialic acid receptors on the surface of infected cells, trapping newly formed viral particles and preventing their release and subsequent infection of neighboring cells. This reduces viral replication and shortens the duration and severity of influenza infection.
Approved indications
- Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age
- Prophylaxis of influenza A and B in patients ≥1 year of age
Common side effects
- Nausea
- Vomiting
- Headache
- Abdominal pain
Key clinical trials
- Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza (PHASE3)
- A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension (PHASE3)
- Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms (PHASE3)
- Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza (PHASE2, PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- Catalysing the Containment of COVID-19 (PHASE2, PHASE3)
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- active oseltamivir CI brief — competitive landscape report
- active oseltamivir updates RSS · CI watch RSS
- University of Oxford portfolio CI